Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Capital Expenditures (2016 - 2025)

Conmed (CNMD) has disclosed Capital Expenditures for 16 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures rose 26.51% year-over-year to $5.1 million, compared with a TTM value of $19.8 million through Dec 2025, up 51.38%, and an annual FY2025 reading of $19.8 million, up 51.38% over the prior year.
  • Capital Expenditures was $5.1 million for Q4 2025 at Conmed, down from $5.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $6.7 million in Q3 2022 and bottomed at $2.0 million in Q1 2024.
  • Average Capital Expenditures over 5 years is $4.4 million, with a median of $4.4 million recorded in 2023.
  • The sharpest move saw Capital Expenditures surged 90.75% in 2022, then plummeted 52.16% in 2024.
  • Year by year, Capital Expenditures stood at $3.2 million in 2021, then skyrocketed by 78.04% to $5.7 million in 2022, then decreased by 14.46% to $4.9 million in 2023, then dropped by 16.79% to $4.0 million in 2024, then increased by 26.51% to $5.1 million in 2025.
  • Business Quant data shows Capital Expenditures for CNMD at $5.1 million in Q4 2025, $5.2 million in Q3 2025, and $5.7 million in Q2 2025.